Dohj LLC Makes New Investment in Stryker Corporation $SYK

Key Points

• Dohj LLC has acquired a new stake in Stryker Corporation, purchasing 1,191 shares valued at approximately $471,000 during the 2nd quarter.
• Stryker recently reported earnings of $3.13 per share, surpassing analysts' expectations, with revenue of $6.02 billion for the quarter, up by 11.1% from the previous year.
• The company declared a quarterly dividend of $0.84 per share, expected to be paid on October 31st, representing a 0.9% dividend yield.

Dohj LLC acquired a new stake in Stryker Corporation (NYSE:SYK - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,191 shares of the medical technology company's stock, valued at approximately $471,000.

Several other institutional investors have also recently made changes to their positions in SYK. Sachetta LLC raised its position in shares of Stryker by 58.7% during the second quarter. Sachetta LLC now owns 73 shares of the medical technology company's stock valued at $29,000 after buying an additional 27 shares during the last quarter. Goodman Advisory Group LLC bought a new stake in Stryker in the 1st quarter valued at $32,000. City Holding Co. lifted its stake in Stryker by 528.6% in the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company's stock worth $33,000 after purchasing an additional 74 shares in the last quarter. Ridgewood Investments LLC boosted its holdings in shares of Stryker by 48.4% during the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company's stock valued at $36,000 after purchasing an additional 30 shares during the last quarter. Finally, Ransom Advisory Ltd bought a new position in shares of Stryker during the 1st quarter valued at about $37,000. Hedge funds and other institutional investors own 77.09% of the company's stock.

Analyst Upgrades and Downgrades

SYK has been the topic of several research reports. Needham & Company LLC lifted their target price on Stryker from $442.00 to $448.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Weiss Ratings restated a "buy (b-)" rating on shares of Stryker in a report on Saturday, September 27th. BTIG Research reaffirmed a "buy" rating on shares of Stryker in a report on Monday, July 14th. Wall Street Zen downgraded Stryker from a "buy" rating to a "hold" rating in a research report on Friday, September 26th. Finally, Wells Fargo & Company boosted their price target on shares of Stryker from $435.00 to $445.00 and gave the stock an "overweight" rating in a research report on Friday, August 1st. Fifteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $430.10.

Stryker Stock Performance

NYSE:SYK opened at $369.14 on Wednesday. The firm has a market capitalization of $141.12 billion, a PE ratio of 48.89, a PEG ratio of 2.64 and a beta of 0.94. The stock's fifty day moving average is $381.50 and its 200 day moving average is $378.86. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating analysts' consensus estimates of $3.07 by $0.06. The business had revenue of $6.02 billion for the quarter, compared to analysts' expectations of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business's revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, sell-side analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker's dividend payout ratio is presently 44.50%.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the sale, the director directly owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Viju Menon sold 500 shares of the business's stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider directly owned 12,511 shares of the company's stock, valued at $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by company insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.